2. Miao B., Hernandez A.V., Alberts M.J. et al. Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors. J Am Heart Assoc. 2020; 9(2): e014402.

https://doi.org/10.1161/jaha.119.014402. PMID: 31937196. PMCID: PMC7033849.

3. Переверзева К.Г., Лукьянов М.М., Андреенко Е.Ю. с соавт. Амбулаторный регистр больных, перенесших инфаркт миокарда (РЕГАТА): данные проспективного наблюдения и результаты. Кардиология. 2022; 62(2): 12–19. (Pereverzeva K.G., Lukyanov M.M., Andreenko E.Yu. et al. Outpatient register of patients who have suffered a myocardial infarction (REGATA): Prospective follow-up data and outcomes. Kardiologiya = Cardiology. 2022; 62(2): 12–19 (In Russ.)).

https://doi.org/10.18087/cardio.2022.2.n1712. EDN: IXLZZV.

4. De Luca L. Low-dose rivaroxaban: Can cardiovascular events be reduced? Eur Hear J Suppl. 2023; 25(Suppl C): C20–C26.

https://doi.org/10.1093/eurheartjsupp/suad034. MID: 37125297. PMCID: PMC10132608.

5. Eikelboom J.W., Connolly S.J., Bosch J. et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377(14): 1319–30.

https://doi.org/10.1056/nejmoa1709118. PMID: 28844192.

6. Комаров А.Л., Шахматова О.О., Коробкова В.В. с соавт. Факторы риска и исходы желудочно-кишечных кровотечений у больных стабильной ишемической болезнью сердца: данные наблюдательного регистра длительной антитромботической терапии РЕГАТА-1. Российский кардиологический журнал. 2021; 26(6): 51–60. (Komarov A.L., Shakhmatova O.O., Korobkova V.V. et al. Risk factors and outcomes of gastrointestinal bleeding in patients with stable coronary artery disease: Data from the observational registry of long-term antithrombotic therapy REGATTA-1. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(6): 51–60 (In Russ.)).

https://doi.org/10.15829/1560-4071-2021-4465. EDN: HRVVZO.

7. Ливзан М.А., Ширинская Н.В. Гастроинтестинальные осложнения у пациентов, получающих антитромботическую и антикоагулянтную терапию. Consilium Medicum. 2019; 21(8): 71–73. (Livzan M.A., Shirinskaya N.V. Gastrointestinal complications in patients receiving antiplatelet and anticoagulant therapy. Consilium Medicum. 2019; 21(8): 71–73 (In Russ.)).

https://doi.org/10.26442/20751753.2019.8.190531. EDN: XLAFRC.

8. Барбараш О.Л., Карпов Ю.А., Панов А.В. с соавт. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(9): 6110. (Barbarash O.L., Karpov Yu.A., Panov A.V. et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal ofCardiology. 2024; 29(9): 6110 (In Russ.)).

https://doi.org/10.15829/1560-4071-2024-6110.

9. Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: Why doesn’t the stomach digest itself? Physiol Rev. 2008; 88(4): 1547–65.

https://doi.org/10.1152/physrev.00004.2008. PMID: 18923189.

10. Graham D.Y., Smith J.L. Aspirin and the stomach. Ann Intern Med. 1986; 104(3): 390–98.

https://doi.org/10.7326/0003-4819-104-3-390. PMID: 3511824.

11. Sostres C., Gargallo C.J., Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013; 15(Suppl 3): S3.

https://doi.org/10.1186/ar4175. PMID: 24267289. PMCID: PMC3890944.

12. de Abajo F.J., García Rodríguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001; 1: 1.

https://doi.org/10.1186/1472-6904-1-1. PMID: 11228592. PMCID: PMC32172.

13. Fork F.T., Lafolie P., Tóth E., Lindgärde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol. 2000; 35(5): 464–69.

https://doi.org/10.1080/003655200750023705. PMID: 10868447.

14. Luo J.-C., Huo T.-I., Hou M.-C. et al. Clopidogrel delays gastric ulcer healing in rats. Eur J Pharmacol. 2012; 695(1–3): 112–19.

https://doi.org/10.1016/j.ejphar.2012.07.054. PMID: 22975710.

15. Tang C., Zhu Y., Yang X. et al. Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. J Gastroenterol Hepatol. 2020; 35(10): 1720–30.

https://doi.org/10.1111/jgh.15030. PMID: 32154936.

16. Han Y., Liao Z., Li Y. et al. Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury. J Am Coll Cardiol. 2022; 79(2): 116–28.

https://doi.org/10.1016/j.jacc.2021.10.028. PMID: 34752902.

17. Голендяева П.И., Ливзан М.А., Гаус О.В. с соавт. Гастропатии, ассоциированные с приемом антиагрегантов и антикоагулянтов: распространенность и факторы риска. Терапия. 2023; 9(8): 75–83. (Golendyaeva P.I., Livzan M.A., Gaus O.V. et al. Gastropathy associated with antiplatelet and anticoagulant therapy: Prevalence and risk factors. Terapiya = Therapy. 2023; 9(8): 75–83 (In Russ.)).

https://dx.doi.org/10.18565/therapy.2023.8.75-83. EDN: JWVHEP.

18. Mihalkanin L., Stancak B. The impact of novel anticoagulants on the upper gastrointestinal tract mucosa. Medicina (Kaunas). 2020; 56(7): 363.

https://doi.org/10.3390/medicina56070363. PMID: 32708292. PMCID: PMC7404461.

19. Wang C.-L., Huang C.-H., Wu V.C.-C. et al. Safety and effectiveness of direct oral anticoagulants vs warfarin in patients with atrial fibrillation and endoscopy-diagnosed peptic ulcer. Front Cardiovasc Med. 2021; 8: 774072.

https://doi.org/10.3389/fcvm.2021.774072. PMID: 35004890. PMCID: PMC8732988.

20. Veitch A.M., Radaelli F., Alikhan R. et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroente­ro­logy (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy. 2021; 53(9): 947–69.

https://doi.org/10.1055/a-1547-2282. PMID: 34359080. PMCID: PMC8390296.

21. Moayyedi P., Eikelboom J.W., Bosch J. et al.; COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, souble-blind, placebo-controlled trial. Gastroenterology. 2019; 157(2): 403–412.e5.

https://doi.org/10.1053/j.gastro.2019.04.041. PMID: 31054846.

22. Lanas A. We are using too many PPIs, and we need to stop: A European perspective. Am J Gastroenterol. 2016; 111(8): 1085–86.

https://doi.org/10.1038/ajg.2016.166. PMID: 27166129.

23. Moriarty F., Bennett K., Cahir C., Fahey T. Characterizing potentially inappropriate prescribing of proton pump inhibitors in older people in primary care in Ireland from 1997 to 2012. J Am Geriatr Soc. 2016; 64(12): e291–e296.

https://doi.org/10.1111/jgs.14528. PMID: 27996115.

24. Lassalle M., Le Tri T., Bardou M. et al. Use of proton pump inhibitors in adults in France: A nationwide drug utilization study. Eur J Clin Pharmacol. 2020; 76(3): 449–57.

https://doi.org/10.1007/s00228-019-02810-1. PMID: 31838548.

25. Savarino V., Dulbecco P., de Bortoli N. et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2017; 37: 19–24.

https://doi.org/10.1016/j.ejim.2016.10.007. PMID: 27784575.

26. Sattayalertyanyong O., Thitilertdecha P., Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: A prospective cross-sectional study. Int J Clin Pharm. 2020; 42(1): 174–83.

https://doi.org/10.1007/s11096-019-00955-8. PMID: 31865594.

27. Tawam D., Baladi M., Jungsuwadee P. et al. The positive association between proton pump inhibitors and clostridium difficile infection. Inov Pharm. 2021; 12(1): 10.24926/iip.v12i1.3439.

https://doi.org/10.24926/iip.v12i1.3439. PMID: 34007671. PMCID: PMC8102963.

28. Blank M.-L., Parkin L., Paul C., Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014; 86(4): 837–44.

https://doi.org/10.1038/ki.2014.74. PMID: 24646856. PMCID: PMC4184187.

29. Hart E., Dunn T.E., Feuerstein S., Jacobs D.M. Proton pump inhibitors and risk of acute and chronic kidney disease: A retrospective cohort study. Pharmacotherapy. 2019; 39(4): 443–53.

https://doi.org/10.1002/phar.2235. PMID: 30779194. PMCID: PMC6453745.

30. Nochaiwong S., Ruengorn C., Awiphan R. et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: A systematic review and meta-analysis. Nephrol Dial Transplant. 2018; 33(2): 331–42.

https://doi.org/10.1093/ndt/gfw470. PMID: 28339835.

31. Wijarnpreecha K., Thongprayoon C., Chesdachai S. et al. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: A meta-analysis. Dig Dis Sci. 2017; 62(10): 2821–27.

https://doi.org/10.1007/s10620-017-4725-5. PMID: 28836158.

32. Трухан Д.И., Филимонов С.Н. Побочные эффекты ингибиторов протонной помпы при длительном применении: в фокусе органы дыхания. Медицина в Кузбассе. 2024; 23(1): 5–10. (Trukhan D.I., Filimonov S.N. Side effects of proton pump inhibitors during long term use: Focus on the respiratory organs. Meditsina v Kuzbasse = Medicine in Kuzbass. 2024; 23(1): 5–10 (In Russ.)).

https://doi.org/10.24412/2687-0053-2024-1-5-10. EDN: SOGMZA.

33. Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И. с соавт. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017; (2): 3–21. (Lazebnik L.B., Tkachenko E.I., Abdulganieva D.I. et al. VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter pylori-associated diseases (VI Moscow agreement). Eksperimentalnaya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2017; (2): 3–21 (In Russ.)). EDN: YHTWEX.

34. Gommers L.M.M., Hoenderop J.G.J., de Baaij J.H.F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022; 235(4): e13846.

https://doi.org/10.1111/apha.13846. PMID: 35652564. PMCID: PMC9539870.

35. Драпкина О.М., Шепель Р.Н. Связь между дефицитом витамина В12, риском развития сердечно-сосудистых заболеваний и процессами старения. Рациональная фармакотерапия в кардиологии. 2017; 13(1): 100–106. (Drapkina O.M., Shepel R.N. The link between vitamin В12 deficiency, risk of cardiovascular ciseases and aging process. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2017; 13(1): 100–106 (In Russ.)).

http://dx.doi.org/10.20996/1819-6446-2017-13-1-100-106. EDN: YGAGLR.

36. Hamano H., Niimura T., Horinouchi Y. et al. Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. Toxicol Lett. 2020; 318: 86–91.

https://doi.org/10.1016/j.toxlet.2019.10.016. PMID: 31669099.

37. Maideen N.M.P. Adverse effects associated with long-term use of proton pump inhibitors. Chonnam Med J. 2023; 59(2): 115–27.

https://doi.org/10.4068/cmj.2023.59.2.115. PMID: 37303818. PMCID: PMC10248387.

38. Thong B.K.S., Ima-Nirwana S., Chin K.-Y. Proton pump Inhibitors and fracture risk: A review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019; 16(9): 1571.

https://doi.org/10.3390/ijerph16091571. PMID: 31060319. PMCID: PMC6540255.

39. Salvo E.M., Ferko N.C., Cash S.B. et al. Umbrella review of 42 systematic reviews with meta-analyses: The safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021; 54(2): 129–43.

https://doi.org/10.1111/apt.16407. PMID: 34114655.

40. Rainsford K.D., Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci. 1982; 27(7): 624–35.

https://doi.org/10.1007/BF01297219. PMID: 6953009.

41. Ивашкин В.Т., Маев И.В., Царьков П.В. с соавт. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020; 30(1): 49–70. (Ivashkin V.T., Mayev I.V., Tsar’kov P.V. et al. Diagnosis and treatment of peptic ulcer in adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Rossiiskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020; 30(1): 49–70 (In Russ.)).

https://doi.org/10.22416/1382-4376-2020-30-1-49-70. EDN: IMFOZP.

42. Остроумова О.Д., Кочетков А.И., Батюкина С.В. с соавт. Гастропротективная терапия у пациентов с фибрилляцией предсердий, получающих антикоагулянтную терапию. Consilium Medicum. 2023; 25(5): 368–374. (Ostroumova O.D., Kochetkov A.I., Batyukina S.V. et al. Gastroprotective therapy in patients with atrial fibrillation receiving anticoagulant therapy: A review. Consilium Medicum. 2023; 25(5): 368–374 (In Russ.)).

https://doi.org/10.26442/20751753.2023.5.202294. EDN: UMCJFE.

43. Sobieraj D.M., White C.M., Alikhanov S. et al. The impact of antiplatelet and anticoagulant therapies on gastrointestinal symptoms in patients with atrial fibrillation: A systematic review. Ann Pharmacother. 2012; 46(9): 1220–31.

https://doi.org/10.1345/aph.1R064. PMID: 22932307.

44. Yamashita T., Watanabe E., Ikeda T. et al. Observational study of the effects of dabigatran on gastrointestinal symptoms inpatients with non-valvular atrial fibrillation. J Arrhythm. 2014; 30(6): 478–84.

https://doi.org/10.1016/j.joa.2014.02.011.

45. Kim J.E., Lee Y.C., Kim T.S. et al. Rebamipide prevents the hemoglobin drop related to mucosal-damaging agents at a level comparable to proton pump inhibitors. Gut Liver. 2024.

https://doi.org/10.5009/gnl230372. PMID: 38468192.

46. Wallace J.L. NSAID gastropathy and enteropathy: Distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012; 165(1): 67–74.

https://doi.org/10.1111/j.1476-5381.2011.01509.x. PMID: 21627632. PMCID: PMC3252967.

47. Tanigawa T., Watanabe T., Otani K. et al. Rebamipide inhibits indomethacin-induced small intestinal injury: Possible involvement of intestinal microbiota modulation by upregulation of α-defensin 5. Eur J Pharmacol. 2013; 704(1–3): 64–69.

https://doi.org/10.1016/j.ejphar.2013.02.010. PMID: 23428631.

48. Lee M.Y., Lee S., Heo K.-N. et al. Rebamipide as a potential alternative gastroprotective agent to proton pump inhibitor in elderly chronic nonsteroidal anti-inflammatory drug users without risk factors. Int J Gen Med. 2022; 15: 2835–45.

https://doi.org/10.2147/ijgm.s353098. PMID: 35300126. PMCID: PMC8922238.

49. Oh D.J., Yoon H., Kim H.S. et al. The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: A multi-center, randomized pilot study. Korean J Intern Med. 2022; 37(6): 1153–66.

https://doi.org/10.3904/kjim.2021.216. PMID: 36375487. PMCID: PMC9666262.

50. Драпкина О.М., Концевая А.В., Калинина А.М. с соавт. Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-терапевта. Евразийское руководство. Кардиоваскулярная терапия и профилактика. 2024; 23(3): 113–418. (Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2024; 23(3): 113–418 (In Russ.)).

https://doi.org/10.15829/1728-8800-2024-3996. EDN: AVZLPJ.

51. Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS One. 2015; 10(4): e0122330.

https://doi.org/10.1371/journal.pone.0122330. PMID: 25874951. PMCID: PMC4398323.

52. Kamada T., Sato M., Tokutomi T. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: A multicenter study. Biomed Res Int. 2015; 2015: 865146.

https://doi.org/10.1155/2015/865146. PMID: 26060821. PMCID: PMC4427810.

53. Han X., Jiang K., Wang B. et al. Effect of rebamipide on the premalignant progression of chronic gastritis: A randomized controlled study. Clin Drug Investig. 2015; 35(10): 665–73.

https://doi.org/10.1007/s40261-015-0329-z. PMID: 26369655.

54. Кочетков А.И., Остроумова О.Д., Переверзев А.П. с соавт. Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Терапия. 2021; 7(10): 23–41. (Kochetkov A.I., Ostroumova O.D., Pereverzev A.P. et al. Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Terapiya = Therapy. 2021; 7(10): 23–41 (In Russ.)).

https://dx.doi.org/10.18565/therapy.2021.10.23-41. EDN: CSPHUF.

55. Drusch S., Neumann A., Michelon H. et al. Do proton pump inhibitors reduce upper gastrointestinal bleeding in older patients with atrial fibrillation treated with oral anticoagulants? A nationwide cohort study in France. Drugs Aging. 2024; 41(1): 65–76.

https://doi.org/10.1007/s40266-023-01085-7. PMID: 38114724. PMCID: PMC10769917.